Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?

SIMPLE SUMMARY: Treatment modalities for sarcoma have not changed significantly for the past few years despite 25–50% of patients experiencing relapse or progressing to metastatic diseases that become resistant to standard of care therapy, indicating an unmet need for better treatment strategies. Wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Chew, Hui Yi, Chan, Victor, Simpson, Fiona, Dolcetti, Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697818/
https://www.ncbi.nlm.nih.gov/pubmed/33207697
http://dx.doi.org/10.3390/cancers12113392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697818/
https://www.ncbi.nlm.nih.gov/pubmed/33207697
http://dx.doi.org/10.3390/cancers12113392

Ejemplares similares